1-7 of 7
Robert Corringham
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results

Jorge E. Cortes, Alexander E Perl, MD, Catherine C. Smith, MD, Tibor Kovacsovics, MD, Herve Dombret, Hartmut Dohner, MD, Bjorn Steffen, MD, Arnaud Pigneux, MD, PhD, Philippe Rousselot, MD, PhD, Juergen Krauter, MD, Giovanni Martinelli, MD, Elihu H. Estey, MD, Alan K Burnett, MD, Anthony D. Ho, Norbert Ifrah, Theo de Witt, MD, Robert Corringham, MD, Joyce James, PhD, David Lilienfeld, MD, Eugen Leo, MD, PhD, MBA, Guy Gammon, MD, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2576.
https://doi.org/10.1182/blood.V118.21.2576.2576
Published: 2011
Journal Articles

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Jorge Cortes, MD, James Foran, MD, Darejan Ghirdaladze, MD, PhD, Marcel P DeVetten, MD, Mamia Zodelava, MD, PhD, Peter Holman, MD, Mark J Levis, MD, PhD, Hagop M Kantarjian, MD, Gautam Borthakur, MD, Joyce James, PhD, Patrick P Zarringkar, PhD, Ruwanthi N Gunawardane, PhD, Robert C Armstrong, PhD, Norman M Padre, Wendell Wierenga, PhD, Robert Corringham, MD, Mohit Trikha, PhD
Journal: Blood
Blood (2009) 114 (22): 636.
https://doi.org/10.1182/blood.V114.22.636.636
Published: 2009
Journal Articles

Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor

Jorge E. Cortes, Darejan Ghirdaladze, James M. Foran, Marcel P. DeVetten, Mamia Zodelava, Mark J. Levis, Norman M. Padre, James Joyce, Patrick P. Zarrinkar, Robert Corringham
Journal: Blood
Blood (2008) 112 (11): 767.
https://doi.org/10.1182/blood.V112.11.767.767
Published: 2008
Journal Articles

Enhancing Activity of Bortezomib Against Multiple Myeloma (MM) through Inhibition of Interleukin (IL)-6 Signaling: A Role for Repression of Myeloid Cell Leukemia (Mcl)-1.

Peter M. Voorhees, George W. Small, Deborah J. Kuhn, Qing Chen, Sally A. Hunsucker, Robert Corringham, Carlos A. Garay, Mohamed H. Zaki, Jeffrey Nemeth, Robert Z. Orlowski
Journal: Blood
Blood (2006) 108 (11): 3414.
https://doi.org/10.1182/blood.V108.11.3414.3414
Published: 2006
Journal Articles

CNTO328 Abrogates Glucocorticoid (GC) Resistance Conferred by Interleukin (IL)-6 and the Bone Marrow Microenvironment in Multiple Myeloma (MM).

Peter M. Voorhees, George W. Small, Deborah J. Kuhn, Qing Chen, Sally A. Hunsucker, Robert Corringham, Carlos A. Garay, Mohamed H. Zaki, Jeffrey Nemeth, Robert Z. Orlowski
Journal: Blood
Blood (2006) 108 (11): 3473.
https://doi.org/10.1182/blood.V108.11.3473.3473
Published: 2006
Journal Articles

Inhibition of Interleukin-6 Signaling with CNTO328 Sensitizes Multiple Myeloma Cells to Bortezomib and Attenuates Proteasome Inhibitor-Mediated Induction of the Anti-Apoptotic Heat Shock Protein Response.

Peter M. Voorhees, MD, Deborah J. Kuhn, PhD, George W. Small, PhD, John S. Strader, PA, Robert Corringham, MD, Mohamed H. Zaki, MD, PhD, Jeffrey Nemeth, PhD, Robert Z. Orlowski, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 1574.
https://doi.org/10.1182/blood.V106.11.1574.1574
Published: 2005
Journal Articles

Interterleukin-6 (IL-6) Produced by Monocyte Activation Reduces Dendritic Cell (DC) Differentiation in Patients with Multiple Myeloma (MM) and Malignant Lymphoma (ML): Role of CNTO 328, an Anti-IL-6 Monoclonal Antibody (Mab) and Possible Clinical Applications.

Jean-Francois Rossi, MD PhD, Anne-Marie Conge, PhD, Catherine Barjot, PhD, Mohamed H. Zaki, PhD, Marian T. Nakada, MD, Robert Corringham, PhD, Bernard Klein
Journal: Blood
Blood (2004) 104 (11): 2662.
https://doi.org/10.1182/blood.V104.11.2662.2662
Published: 2004